Literature DB >> 22293044

Primary high-risk HPV screening for cervical cancer in post-menopausal women.

Ulf Gyllensten1, Inger Gustavsson, Monica Lindell, Erik Wilander.   

Abstract

OBJECTIVE: The present study was conducted to examine the value of screening for high-risk HPV in post-menopausal women.
METHODS: A cohort of post-menopausal women (n=2113), age range 55-76 years, from Uppsala County, Sweden, were offered testing for both high-risk HPV and a Pap smear in the gynaecological screening during 2008-2010. For the HPV test the cervical smear sample was applied to a filter paper matrix, an indicating FTA elute card and HPV typing performed using a real-time PCR assay. Histological verified CIN2+ lesion was used as an end-point measurement.
RESULTS: High-risk HPV were found in 6.2% (95% CI 5.2-7.3%) of the women (n=130) and 22% (95% CI 14-32%) (n=17) of these had CIN2+ lesions based on histology. The Pap smear taken in conjunction with the HPV test was abnormal in 9.7% (95% CI 5.7-16.3%) (n=12) of HPV positive women. Among HPV positive women with an abnormal Pap smear, the frequency of histology verified CIN2+ lesions was 67% (95% CI 38-86%) (n=8), as compared to 14% (95% CI 7-24%) (n=9) in HPV positive women with a normal smear. The prevalence of HPV16 in CIN2+ lesions (29%, 95% CI 22-37%) in post-menopausal women was less than half of previous estimates in pre-menopausal women from this population.
CONCLUSIONS: Most histological CIN2+ lesions in post-menopausal women are not recognized by a single Pap smear. A large fraction of pre-invasive cervical cancer cases in post-menopausal women result from infections by HPV types not included in the present vaccine formulas.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22293044     DOI: 10.1016/j.ygyno.2012.01.036

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  16 in total

1.  Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer.

Authors:  Yi Li; Tao Wu; Beilei Zhang; Yuanqing Yao; Guowu Yin
Journal:  Med Oncol       Date:  2012-06-30       Impact factor: 3.064

2.  Cervical Cancer Screening in Postmenopausal Women: Is It Time to Move Toward Primary High-Risk Human Papillomavirus Screening?

Authors:  Jaime M Kiff; Madisen Cotter; Elizabeth G Munro; Molly E Leonard; Terry K Morgan; Amanda S Bruegl
Journal:  J Womens Health (Larchmt)       Date:  2021-04-07       Impact factor: 3.017

3.  A very rare case of HPV-53-related cervical cancer, in a 79-year-old woman with a previous history of negative Pap cytology.

Authors:  Roberta Zappacosta; Giuseppe Lattanzio; Patrizia Viola; Manuel Maria Ianieri; Daniela Maria Pia Gatta; Sandra Rosini
Journal:  Clin Interv Aging       Date:  2014-04-15       Impact factor: 4.458

4.  HPV prevalence and HPV-related dysplasia in elderly women.

Authors:  Ruth S Hermansson; Matts Olovsson; Emelie Hoxell; Annika K Lindström
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

5.  Protein Detection Using the Multiplexed Proximity Extension Assay (PEA) from Plasma and Vaginal Fluid Applied to the Indicating FTA Elute Micro Card™.

Authors:  Malin Berggrund; Daniel Ekman; Inger Gustavsson; Karin Sundfeldt; Matts Olovsson; Stefan Enroth; Ulf Gyllensten
Journal:  J Circ Biomark       Date:  2016-01-01

6.  Cervical Cytopathological Changes Associated with Onset of Menopause.

Authors:  Jata Shanker Misra; Anand Narain Srivastava; Zeeshan Haider Zaidi
Journal:  J Midlife Health       Date:  2018 Oct-Dec

7.  Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ.

Authors:  Sonia Andersson; Miriam Mints; Erik Wilander
Journal:  Oncol Lett       Date:  2013-05-15       Impact factor: 2.967

8.  Uneven distribution of human papillomavirus 16 in cervical carcinoma in situ and squamous cell carcinoma in older females: A retrospective database study.

Authors:  Sonia Andersson; Miriam Mints; Ulf Gyllensten; Monica Lindell; Inger Gustavsson; Mats Lambe; Erik Wilander
Journal:  Oncol Lett       Date:  2014-07-11       Impact factor: 2.967

Review 9.  Cervical Cancer Screening after Perimenopause: How Is Human Papillomavirus Test Performed?

Authors:  Soo-Ho Chung
Journal:  J Menopausal Med       Date:  2016-08-30

10.  Performance and acceptability of self-collected human papillomavirus testing among women living with HIV.

Authors:  Runzhi Wang; Kristen Lee; Charlotte A Gaydos; Jean Anderson; Jean Keller; Jenell Coleman
Journal:  Int J Infect Dis       Date:  2020-07-30       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.